Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
-
BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
-
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology
-
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 M
-
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology
-
BioStem Technologies CEO to Present at Biotech Showcase 2025
-
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
-
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
-
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
-
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All MAC Regions